MedTrace Logo

Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.

NCT01226368 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 455

Last updated 2014-10-30

No results posted yet for this study

Summary

Cervical cancer is a public health problem. In term of frequency and mortality, it represents in Martinique the third localization the most frequently diagnosed and the fifth cause of death by cancer. Cervical cancer is recognized as viro-inducted. Human papillomavirus (HPV) is the etiologic agent, as a necessary but not sufficient cause, in the cancer genesis. It is estimated than about 70 to 80% of women have been or will be infected with an HPV in their genital life, the risks factors being those of the others sexually transmitted diseases (STD). Most of HPV infection are transient, by spontaneous clearance in a few months of the virus under episomal form.

Carcinogen risk is related to viral persistency which inducts the condition of cellular transformation.

Infection persistency and subsequent carcinogen risk depend of the genotype concerned and of the host immunitary response.

HIV infection is known to be associated with an higher prevalency of one or several infection with HPV-HR.

However, no data about HIV/HPV coinfection prevalency are available nowadays in French overseas department of South America whereas they are the most affected by HIV.

Conditions

  • 1- Women
  • 2- HIV Infection
  • 3- Followed in West Indies and French Guiana for His Infection
  • 4- Acceptance of the Use of Nadis® Medical Files

Interventions

OTHER

Biological Sample collection

Cervix cells

Sponsors & Collaborators

  • Fondation de France

    collaborator OTHER

  • Clinique Antilles-Guyane

    collaborator OTHER

  • University Hospital Center of Martinique

    lead OTHER

Principal Investigators

  • Sylvie ABEL, MD · University Hospital Center of Martinique

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-01-31
Completion
2014-03-31

Countries

  • Martinique

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226368 on ClinicalTrials.gov